Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Casi Pharmaceuticals Appoints Daniel Lang, Md As Chief Financial Officer and Senior Vice President

PUBLIC · CASIFJul 08, 2024•almost 2 years ago

Position

Vice President

Company

CASI Pharmaceuticals

Daniel Lang

RockvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

CASI Pharmaceuticals, Inc. announces the appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President. Dr

Company Information

Company

CASI Pharmaceuticals

Location

Medical Center Drive

Rockville, Maryland, United States

About

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for CASI Pharmaceuticals's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months